Results 41 to 50 of about 95,190 (307)
Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024
FEBS Open Bio, EarlyView.The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior +5 more
wiley +1 more source
Haematologica, 2012 Background A subset of patients with fludarabine-resistant chronic lymphocytic leukemia has previously been shown to express elevated intracellular levels of the concentrative high-affinity fludarabine transporter hCNT3, without any detectable related ...
Paula X. Fernández-Calotti +3 more
doaj +1 more source
Advanced Biology, EarlyView.The novelty of this study showed that the injection of exosomes produced from ADMSCs in combination with Roflumilast poses a more favorable therapeutic outcome for CKD induced by Adriamycin, compared to therapy with exosomes or Roflumilast alone. Roflumilast and exosomes treatment lowered the expression of the apoptotic, fibrotic, and inflammatory ...
Mohamed Ali +5 more
wiley +1 more source
Haematologica, 2015 Lenalidomide is an immunomodulatory agent clinically active in chronic lymphocytic leukemia patients. The specific mechanism of action is still undefined, but includes modulation of the microenvironment.
Stefania Fiorcari +11 more
doaj +1 more source
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Advanced Functional Materials, EarlyView.Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source
Annals of Oncology, 2010 The management of chronic lymphocytic leukemia (CLL) is currently undergoing a profound change. First, several new drugs have been approved (fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab). In addition, novel monoclonal antibodies targeting CD20, CD23, CD37 or CD40, as well as drugs designed to interfere with central
Michael, Hallek, Natali, Pflug
openaire +2 more sources
Harnessing Photo‐Energy Conversion in Nanomaterials for Precision Theranostics
Advanced Materials, EarlyView.Harnessing photo‐energy conversion in nanomaterials enables precision theranostics through light‐driven mechanisms such as photoluminescence, photothermal, photoelectric, photoacoustic, photo‐triggered surface‐enhanced Raman scattering (SERS), and photodynamic processes. This review explores six fundamental principles of photo‐energy conversion, recent
Jingyu Shi +4 more
wiley +1 more source
SAGE Open Medical Case Reports, 2018 Kaposi’s sarcoma is a neoplasm of endothelial cells. That vascular tumor is usually limited to the skin, but it may involve mucous membranes, visceral organs, and lymph nodes.
Damir Vučinić +5 more
doaj +1 more source
Haematologica, 2012 Background The levels and clinical relevance of Th17 cells and other interleukin-17-producing cells have not been analyzed in chronic lymphocytic leukemia.
Preetesh Jain +15 more
doaj +1 more source
Advancing Clinical Medicine with Raman Spectroscopy: Current Trends and Future Perspectives
Advanced Photonics Research, EarlyView.Raman spectroscopy and microscopy may become excellent tools in clinical medicine, including hematology, oncology, infectious diseases, neurology, gastroenterology, reproductive medicine, rheumatology, and cardiovascular research. However, many challenges such as signal interference, standardization issues, and limited clinical application need to be ...
Jiří Bufka +5 more
wiley +1 more source